Excelimmune, Inc., a biopharmaceutical company, engages in the development of human recombinant polyclonal antibodies for therapeutic use. Developing utting-edge bioinformatics software tools, the company focused on the treatment of infections caused by staphylococcus aureus, including the drug resistant superbug, methicillin-resistant staphylococcus aureus. Excelimmune offers a platform for developing human recombinant polyclonal antibody therapeutics for therapeutic applications, such as the treatment of infectious diseases, protein diseases, and cancer. Principals of the firm appear to have relocated during Summer 2016 and Excelimmune discontinued operations.
